Shire bags a quick thumbs up for its new­ly won can­cer drug pipeline

Shire is ready to cash in its first can­cer drug chip won in its ac­qui­si­tion of Bax­al­ta.

The biotech com­pa­ny says that the EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use has giv­en it a thumbs up on an ap­pli­ca­tion to mar­ket Onivyde — an irinote­can li­po­some in­jec­tion com­bined with 5-flu­o­rouracil and leu­cov­orin to fight metasta­t­ic pan­cre­at­ic can­cer as a sec­ond-line drug af­ter gem­c­itabine ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER